2000
DOI: 10.1128/aac.44.7.2007-2008.2000
|View full text |Cite
|
Sign up to set email alerts
|

Novel Fosfomycin Resistance of Pseudomonas aeruginosa Clinical Isolates Recovered in Japan in 1996

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
9
0

Year Published

2005
2005
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 20 publications
(9 citation statements)
references
References 7 publications
(7 reference statements)
0
9
0
Order By: Relevance
“…Thus, activation of expression of these genes during anaerobic growth may be reasonable from a physiological standpoint for EHEC to reduce the metabolic cost. This concept is also supported by epidemiologic data showing that susceptibility rates have remained relatively stable despite the prevalent use of fosfomycin, though mutants that are resistant to fosfomycin can frequently be isolated from in vitro laboratory cultures (35)(36)(37)(38)(39). A loss of biological fitness, together with conferred resistance, offers the benefit that the development of resistance to the drug could occur with a low possible incidence even if its use increases in the future.…”
Section: Discussionmentioning
confidence: 61%
“…Thus, activation of expression of these genes during anaerobic growth may be reasonable from a physiological standpoint for EHEC to reduce the metabolic cost. This concept is also supported by epidemiologic data showing that susceptibility rates have remained relatively stable despite the prevalent use of fosfomycin, though mutants that are resistant to fosfomycin can frequently be isolated from in vitro laboratory cultures (35)(36)(37)(38)(39). A loss of biological fitness, together with conferred resistance, offers the benefit that the development of resistance to the drug could occur with a low possible incidence even if its use increases in the future.…”
Section: Discussionmentioning
confidence: 61%
“…In support of this hypothesis, mutants that are resistant to fosfomycin can be frequently isolated in vitro (24,25). However, epidemiologic data indicate that susceptibility rates have remained relatively stable since the introduction of this agent in clinical practice (26)(27)(28).…”
mentioning
confidence: 94%
“…Furthermore, the residues highlighted in this channel (with the exception of Trp 46 ) contain a hydroxyl or thiol side chain that could be involved in activating and/or stabilizing GSH/GS Ϫ . The low toxicity and broad-spectrum bactericidal activity of fosfomycin have resulted in its increased clinical use, which in turn has resulted in fosfomycin-resistant strains (7,8). Currently, there are no inhibitors to combat FosA-mediated fosfomycin resistance.…”
mentioning
confidence: 99%